000281874 001__ 281874
000281874 005__ 20251127143337.0
000281874 0247_ $$2doi$$a10.1007/s00259-025-07341-9
000281874 0247_ $$2pmid$$apmid:40445313
000281874 0247_ $$2pmc$$apmc:PMC12589282
000281874 0247_ $$2ISSN$$a1619-7070
000281874 0247_ $$2ISSN$$a1619-7089
000281874 037__ $$aDZNE-2025-01245
000281874 041__ $$aEnglish
000281874 082__ $$a610
000281874 1001_ $$aOnkes, Meike$$b0
000281874 245__ $$a[18F]SiTATE-PET/CT for detection of pheochromocytomas and paragangliomas: comparison of biochemical secretion, genotype and imaging metrics.
000281874 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2025
000281874 3367_ $$2DRIVER$$aarticle
000281874 3367_ $$2DataCite$$aOutput Types/Journal article
000281874 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764250106_8032
000281874 3367_ $$2BibTeX$$aARTICLE
000281874 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281874 3367_ $$00$$2EndNote$$aJournal Article
000281874 520__ $$aSomatostatin-receptor (SSTR)-targeting PET/CT is widely used for diagnosis and disease monitoring of pheochromocytoma / paraganglioma (PPGL). The aim of this study was to assess the potential of the novel SSTR-targeting tracer [18F]SiTATE in diagnosing PPGL by comparing imaging parameters to tumor marker levels and secretory activity in a small cohort of patients diagnosed with this rare tumor type.This retrospective study included 34 patients with histologically confirmed PPGL who underwent [18F]SiTATE-PET/CT at LMU University Hospital Munich between 10/2020 and 02/2024 as well as hormonal laboratory analysis within up to 100 days. Imaging parameters - standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion uptake (TLU) - were analyzed. Uptake was normalized to liver background (SUVmaxr, SUVmeanr). Radioligand uptake of biochemical subtypes and genotypes was compared with Mann-Whitney-U test. Correlation was tested using Spearman´s rank correlation test.The patient-based detection rate of [18F]SiTATE-PET was 96.6%. A moderate correlation was found between MTV and TLU with chromogranin A (r = 0.570-0.608, p < 0.005) and with biochemical secretion (r = 0.466-0.576, p < 0.05). Hereditary PPGL with Cluster 1 genotype showed stronger [18F]SiTATE uptake compared to sporadic PPGL (SUVmeanr: p = 0.032; SUVmaxr: p = 0.051). A subgroup comparison with [⁶⁸Ga]Ga-DOTATOC-PET/CT revealed no significant difference in uptake metrics or tumor-to-background ratios.This is the first clinical evaluation of [18F]SiTATE-PET/CT in patients with PPGL. MTV and TLU measured with [18F]SiTATE-PET/CT correlated well with the tumor marker chromogranin A in serum and with (nor)metanephrines in urine and plasma. Within the limits imposed by the small cohort, our results suggest that TLU and MTV in [18F]SiTATE-PET/CT could be used as SSTR imaging biomarker for monitoring of disease progression and secretory activity in patients with PPGL.
000281874 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000281874 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281874 650_7 $$2Other$$aCatecholamines
000281874 650_7 $$2Other$$aELISA
000281874 650_7 $$2Other$$aLCMS
000281874 650_7 $$2Other$$aMolecular imaging
000281874 650_7 $$2Other$$aPET/CT
000281874 650_7 $$2Other$$aPPGL
000281874 650_7 $$2Other$$aParaganglioma
000281874 650_7 $$2Other$$aPheochromocytoma
000281874 650_7 $$2Other$$aSSTR
000281874 650_7 $$2Other$$a[18F]SiTATE
000281874 650_2 $$2MeSH$$aHumans
000281874 650_2 $$2MeSH$$aPositron Emission Tomography Computed Tomography
000281874 650_2 $$2MeSH$$aMale
000281874 650_2 $$2MeSH$$aPheochromocytoma: diagnostic imaging
000281874 650_2 $$2MeSH$$aPheochromocytoma: genetics
000281874 650_2 $$2MeSH$$aPheochromocytoma: metabolism
000281874 650_2 $$2MeSH$$aFemale
000281874 650_2 $$2MeSH$$aMiddle Aged
000281874 650_2 $$2MeSH$$aAdrenal Gland Neoplasms: diagnostic imaging
000281874 650_2 $$2MeSH$$aAdrenal Gland Neoplasms: genetics
000281874 650_2 $$2MeSH$$aAdrenal Gland Neoplasms: metabolism
000281874 650_2 $$2MeSH$$aAdult
000281874 650_2 $$2MeSH$$aParaganglioma: diagnostic imaging
000281874 650_2 $$2MeSH$$aParaganglioma: genetics
000281874 650_2 $$2MeSH$$aParaganglioma: metabolism
000281874 650_2 $$2MeSH$$aRetrospective Studies
000281874 650_2 $$2MeSH$$aAged
000281874 650_2 $$2MeSH$$aGenotype
000281874 650_2 $$2MeSH$$aYoung Adult
000281874 7001_ $$aDahlmann, Paul$$b1
000281874 7001_ $$aGesenhues, Alena$$b2
000281874 7001_ $$aGacula, Sean Ira G$$b3
000281874 7001_ $$aMansour, Nabeel$$b4
000281874 7001_ $$aSchweizer, Júnia R O L$$b5
000281874 7001_ $$aStüfchen, Isabel$$b6
000281874 7001_ $$aLottspeich, Christian$$b7
000281874 7001_ $$aWang, Katharina$$b8
000281874 7001_ $$aAuer, Matthias K$$b9
000281874 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b10$$udzne
000281874 7001_ $$aFischer, Alessa$$b11
000281874 7001_ $$aBraunschweig, Till$$b12
000281874 7001_ $$aGildehaus, Franz-Josef$$b13
000281874 7001_ $$aLindner, Simon$$b14
000281874 7001_ $$aSchmid-Tannwald, Christine$$b15
000281874 7001_ $$aPfluger, Thomas$$b16
000281874 7001_ $$aAuernhammer, Christoph J$$b17
000281874 7001_ $$aNölting, Svenja$$b18
000281874 7001_ $$aWerner, Rudolf A$$b19
000281874 7001_ $$aReincke, Martin$$b20
000281874 7001_ $$aBidlingmaier, Martin$$b21
000281874 7001_ $$aKroiss, Matthias$$b22
000281874 7001_ $$00000-0001-6157-0363$$aVölter, Friederike$$b23
000281874 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07341-9$$gVol. 52, no. 13, p. 5175 - 5188$$n13$$p5175 - 5188$$tEuropean journal of nuclear medicine and molecular imaging$$v52$$x1619-7070$$y2025
000281874 8564_ $$uhttps://pub.dzne.de/record/281874/files/DZNE-2025-01245%20SUP.pdf
000281874 8564_ $$uhttps://pub.dzne.de/record/281874/files/DZNE-2025-01245.pdf$$yOpenAccess
000281874 8564_ $$uhttps://pub.dzne.de/record/281874/files/DZNE-2025-01245%20SUP.pdf?subformat=pdfa$$xpdfa
000281874 8564_ $$uhttps://pub.dzne.de/record/281874/files/DZNE-2025-01245.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281874 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000281874 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000281874 9141_ $$y2025
000281874 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000281874 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281874 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000281874 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281874 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000281874 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000281874 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000281874 980__ $$ajournal
000281874 980__ $$aVDB
000281874 980__ $$aUNRESTRICTED
000281874 980__ $$aI:(DE-2719)1110007
000281874 9801_ $$aFullTexts